Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Combivir Users Warned About Label-Switching Reports

June/July 2002

GlaxoSmithKline has received four reports of label switching on bottles of pills which should have contained Combivir, but actually contained Ziagen. Manufacturers are warning users of the medication Combivir to inspect their bottles and the tablets themselves prior to use.

While both medications are used to treat HIV infection (and are combined in Trizivir), they have very different side effects. Ziagen side effects can include hypersensitivity, which in some instances can be fatal.

Consumers with questions may call GlaxoSmithKline at (888) 825-5249.


Back to the June/July 2002 issue of Positive Living.

Advertisement

This article has been reprinted at The Body with the permission of AIDS Project Los Angeles (APLA).




  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by AIDS Project Los Angeles. It is a part of the publication Positive Living.
 

Tools
 

Advertisement